Andreessen Horowitz raises $450 million for second bio fund
Andreessen Horowitz has raised $450 million for its second venture capital fund focused on the intersection of biology and computer science.
Why it matters: This is more than double the size of Andressen Horowitz's first bio-focused fund, reflecting more opportunity than the Silicon Valley-based firm had originally expected — including for companies with applications outside of healthcare.
"We really expect this to be the century of biology," says Andreessen Horowitz partner Vijay Pande. "The opportunity right now is that traditional biotech has had to deal with science risk but, through things like machine learning, companies can avoid a lot of that risk."